Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Names New Chairman, Olex Joins RainDance, Peden to Head Znomics' European Operations, and Others

NEW YORK (GenomeWeb News) - Osmetech has named Daryl Faulkner to be non-executive chairman. The company’s current chairman, Gordon Hall, will step down but will remain on the board as a non-executive director.
Faulkner recently was president and CEO of Digene, and he was a senior VP and GM for strategic business and international operations at Invitrogen.
Osmetech also said that Bruce Huebner has retired from the company and has left his position as a director.

Michael Olex has been appointed VP of system development at RainDance Technologies. Olex previously was VP of manufacturing at BioTrove, and he was senior VP at US Genomics, as well as director of Business Projects at Applied Biosystems.

StarLIMS Technologies has named Joe Peden to take over the company’s StarLIMS Europe operations.
Peden formerly was president and COO at Ardenno, and he was senior director of marketing and product management at Thermo Fisher Scientific, where he developed partnerships for the lab information management group.

Znomics has appointed Mark Philip to take over the role of CEO from Richard Sessions, who is the company’s co-founder and who had been serving as interim CEO. Sessions will remain a consultant to the company and will be a member of the company’s board of directors.
Philip has been a senior biotech and pharmaceuticals executive for over 25 years. He was president of Stryker Biotech, he has been president and CEO of Zycos, and he was president and CEO of Immuno International.
Philip also held executive positions at Baxter International and at Schering-Plough Pharmaceuticals.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.